Can the shingles vaccine stave off dementia?

A groundbreaking body of research suggests the shingles vaccine may reduce the risk of developing dementia by up to 20% over seven years—far beyond its intended purpose of preventing shingles. This surprising link emerged from a rare natural experiment in countries like the UK, where eligibility for the vaccine hinged on being born just before or after a specific cutoff date, creating near-identical comparison groups. The findings point to a powerful causal relationship, not just correlation, because the only difference between vaccinated and unvaccinated individuals was a few days of age. Experts like Dr. Pascal Geldsetzer and Dr. Helen Chu argue this could be due to the vaccine’s ability to reduce chronic inflammation caused by reactivated herpes zoster virus, which targets the nervous system and may contribute to vascular dementia. The effect may also stem from broader immune system modulation, especially with live-attenuated vaccines, which appear to boost innate immunity beyond their specific target. While clinical trials are still needed, the data is already compelling enough to suggest that vaccines may play a far more central role in preventing chronic diseases than previously thought.